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ABSTRACT:DeletionofPhe508 fromtheﬁrstnucleotide-
binding domain of the CFTR chloride channel causes cystic
ﬁbrosis because it inhibits protein folding. Indirect ap-
proaches such as incubation at low temperatures can
partially rescue ΔF508 CFTR, but the protein is unstable
at the cell surface. Here, we show that direct binding of
benzbromarone to the transmembrane domains promoted
maturation and stabilized ΔF508 CFTR because its half-life
at the cell surface was ∼10-fold longer than that for low-
temperature rescue. Therefore, a search for small molecules
that can rescue andstabilizeΔF508 CFTRcouldlead tothe
development of an eﬀective therapy for cystic ﬁbrosis.
T
he cystic ﬁbrosis transmembrane conductance regulator
(CFTR) is a cAMP-regulated chloride channel that is
located on the apical surface of epithelial cells that line lung
airways and ducts of various glands (reviewed in ref 1). Its
physiologicalroleistoregulatesaltsecretionandreabsorptionto
maintain normal salt and water homeostasis in epithelial tissues.
Cystic ﬁbrosis is a genetic disease caused by mutations in the
CFTR gene.
2 The most common defect is deletion of Phe508
(ΔF508 CFTR) from the ﬁrst nucleotide-binding domain
(NBD1). ΔF508 CFTR is rapidly degraded in the endoplasmic
reticulum
3andisunstableatthecellsurfacewhenrescuedbylow
temperatures.
4 The ΔF508 mutation appears to alter the folding
kinetics of NBD1
5 and disrupts interactions between NBD1 and
intracellular loop 4 in the second transmembrane domain
(TMD2).
6,7 Disruption of NBD1 TMD2 interactions leads to
defective packing of the TM segments.
8 The lack of functional
CFTR in the airways causes the accumulation of viscous mucus
and colonization with microorganisms that cause inﬂammation
and loss of function.
1
A potential treatment for cystic ﬁbrosis would be to promote
folding of ΔF508 CFTR to increase the amount of protein
delivered to the cell surface. Indirect approaches such as low-
temperature rescue,
9 expression in the presence of “chemical
chaperones” such as glycerol and DMSO,
10,11 perturbing CFTR 
chaperone interactions with agents such as thapsigargin,
12 and
inhibiting ER-associated degradation
13 were shown to yield
mature ΔF508 CFTR at the cell surface that retains some
functional activity. The ΔF508 CFTR rescued with these
approaches is ∼5 10-fold less stable at the cell surface than
wild-type CFTR.
14
Analternative approach torescuing ΔF508 CFTR istomimic
the direct drug-rescue approach described for CFTR’s sister
protein,theP-glycoprotein(P-gp)drugpump.Ithasbeenfound
that direct binding of drug substrates to the transmembrane
domains of P-gp processing mutants stabilizes and promotes
maturation of the protein, resulting in an active molecule at the
cell surface.
15,16
Compounds that speciﬁcally rescue ΔF508 CFTR would
result in fewer side eﬀects as other metabolic pathways would
notbeaﬀected.Thebioavailabilityofthesecompoundswould
be enhanced if they were not substrates of drug pumps such
as P-gp.
There are a number of potential advantages for targeting the
transmembrane domains of CFTR. For example, the TM do-
mains are predicted to be a good target for rescue because
packing of the TM segments during folding appears to be a rate-
limiting step and occurs post-translationally.
17 In addition, many
of the TM segments of mammalian ABC transporters such as
CFTR and P-gp are unstable during synthesis.
18 Finally, it
appears that disruption of domain domain interactions by
mutations such as ΔF508 in mammalian ABC proteins could
yield TM domains with altered topologies.
19 Although it is
possible to promote maturation using compounds that bind to
NBD1,
20 it is possible that they may not stabilize CFTR because
they are still deﬁcient in NBD1 TMD2 interactions because of
the lack of Phe508 at this critical interface.
It was recently reported that the stability of ΔF508 CFTR at
the cell surface approached that of wild-type CFTR when
NBD TMD2 interactions were restored.
21 It was shown that
introduction of a V510D mutation into NBD1 promoted the
maturation and stability of ΔF508 CFTR by forming a a salt
bridgewithArg1070ofTMD2.
21Similarly,maturationofΔF508
CFTR was promoted by a R1070W suppressor mutation in
TMD2.
5Thesesuppressormutationresultssuggestedthatdirect
binding of a compound to the TMDs may promote the matura-
tion and stability of ΔF508 CFTR. To test this prediction, we
tested whether benzbromarone that is thought to bind to the
TMDs
22 could promote maturation of ΔF508 CFTR and
increase its stability at the cell surface.
Accordingly, cells expressing ΔF508 CFTR were incubated in
the presence of various concentrations of benzbromarone for
40 h. In agreement with a previous study of ΔF508 CFTR,
23 no
increase in the level of mature protein was observed when cells
were expressed in the presence of 0 20 μM benzbromarone
(Figure 1A). A potential problem in the initial study was that
benzbromaroneisarelativelylow-aﬃnityCFTRchannelblocker
(Ki = 11.5 μM)
22 and higher concentrations would be needed to
rescueΔF508CFTR.Thiswasindeedthecase,asmatureΔF508
CFTRcouldbereadilydetectedwhencellswereexpressedinthe
presence of 50 75 μM benzbromarone (Figure 1A). Higher
levels appeared to be toxic as the relative amount of mature
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CFTR decreased when cells were incubated in the presence of
100 150 μM benzbromarone.
WetestedwhetherbenzbromaronecouldrescueCFTRwitha
diﬀerent processing mutation. The H1085R mutation is located
in TMD2 within the intracellular loop (ICL) connecting TM10
andTM11.
24MatureproteinwasobservedwhenH1085RCFTR
was expressed in the presence of 38 100 μM benzbromarone
(Figure 1A). The yield of mature CFTR peaked in the presence
of 50 75 μM benzbromarone and then decreased at higher
concentrations.
CFTR’s sister protein, the P-glycoprotein drug pump, was
used to test for the speciﬁcity of benzbromarone rescue. The
G251V processing mutant was selected as it shows an ∼15%
maturation eﬃciency.
25 Figure 1A shows that benzbromarone
did not promote maturation of G251V P-gp.
To test if the CFTR mutants were active after benzbromar-
one rescue, we performed iodide eﬄux assays on BHK cells
stably expressing ΔF508, H1085R, or wild-type CFTR pro-
teins. It was found that both ΔF508 and H1085R exhibited
forskolin-activatediodideeﬄuxafterrescuewithbenzbromar-
one (Figure 1B).
It was shown that benzbromarone appeared to interact with
the CFTR TMDs because 200 μM benzbromarone blocked
cross-linking between cysteines introduced into TM segments
6 and 12 (M348C/T1142C).
23 This concentration of benzbro-
marone is now shown to inhibit maturation of CFTR (Figure 1A).
Wethentestedifabenzbromaroneconcentrationthatpromoted
maturation of CFTR processing mutants (50 μM) also blocked
cross-linking. Figure 1C shows that 50 μM benzbromarone inhi-
bitedcross-linkingbetweenTMD1andTMD2[M348C(TM6)/
T1142C(TM12)] but not between NBD1 and TMD2 [V510C-
(NBD1)/A1067C(ICL4)].
It was possible, however, that benzbromarone interacted with
theNBDsandinhibitedcross-linkingthrough long-rangeeﬀects.
To determine if benzbromarone could modulate folding of the
TMDs alone, we tested its eﬀect on glycosylation of a truncation
mutant lacking both NBDs (TMD1þ2). The mutant is ineﬃ-
cientlycore-glycosylated(Figure1D).Expressioninthepresence
of benzbromarone, however, promoted core glycosylation of
TMD1þ2 (Figure 1D). The ability of benzbromarone to inhibit
cross-linking between TM6 and TM12 (Figure 1C), promote
glycosylation of TMD1þ2 (Figure 1D), and inhibit CFTR
chloride channel activity
26 suggests that it directly interacts with
the TMDs.
Mature ΔF508 CFTR is ∼10-fold less stable than wild-type
CFTR.
14InBHKcells,wefoundthatmatureΔF508CFTRhada
half-life of ∼1.5 h compared to a half-life of ∼14 h for wild-type
CFTR.
8 To test the eﬀect of benzbromarone on ΔF508 CFTR
stability, we performed pulse chase assays in the presence or
absenceof0.05mMbenzbromarone.Benzbromaronepromoted
a slow maturation of ΔF508 CFTR that took ∼4 8 h to reach
maximal levels (Figure 2A). The slow maturation was similar to
what was previously observed with the V510D/ΔF508 CFTR
suppressor mutant.
8 Maturation of mutant V510D/ΔF508
CFTRrequired∼4 8h(Figure2A)comparedto1 2hforthe
wild-type enzyme.
21
The half-life of the mature ΔF508 CFTR in the pulse chase
assays was ∼16 h after rescue with benzbromarone (data not
shown). To measure the stability of ΔF508 CFTR at the cell
surface, cell surface labeling assays were performed. BHK cells
expressing ΔF508 CFTR were incubated overnight at 30 Ci n
the presence or absence of 0.05 mMbenzbromarone topromote
maturation of the protein. The next day, protein synthesis was
stopped by addition of 0.2 mg/mL cycloheximide. Turnover of
ΔF508 CFTR from the cell surface was then monitored by
performing cell surface labeling after various time periods at
37 C (Figure 2B). In the absence of benzbromarone, ΔF508
CFTR had a short half-life of 1.7 ( 0.3 h (Figure 2C). Benz-
bromarone stabilized ΔF508 CFTR as its half-life increased to
18 ( 2 h (Figure 2C).
The results from this study suggest that benzbromarone
directly interacts with the TMDs of CFTR to promote the
Figure 1. Eﬀect of benzbromarone on maturation of CFTR and
P-glycoprotein processing mutants. (A) Immunoblot analysis of cells
expressing CFTR mutant ΔF508 or H1085R or the P-gp G251V
processing mutant after treatment with the indicated concentrations
of benzbromarone (Benz) for 40 h. (B) Iodide eﬄux assays performed
on BHK cells stably expressing wild-type, ΔF508, or H1085R CFTR.
Cells expressing mutant CFTRs were assayed after treatment with
0.05 mM benzbromarone for 40 h. (C) Eﬀect of benzbromarone on
cross-linking (X-link) between cysteines in TMD1 and TMD2
(M348C/T1142C) or NBD1 and TMD2 (V510C/A1067C).
7 (D)
Immunoblot of cells expressing CFTR TMD1þ2 in the absence ( )
orpresence(þ)of0.05mMbenzbromarone.Samplesweretreatedwith
(þ) or without ( ) endoglycosidase H (Endo H).
Figure 2. Eﬀect of benzbromarone on the stability of ΔF508 CFTR.
(A)Pulse chaseassaysofΔF508CFTRperformedinthepresence(þ)
or absence ( ) of 0.05 mM benzbromarone (Benz). (B) Cell surface
labeling performed on cells expressing ΔF508 CFTR in the presence
(þBenz) or absence ( Benz) of 0.05 mM benzbromarone. Cells were
ﬁrst incubated for 24 h at 30 C in the presence (þBenz) or absence
( Benz) of benzbromarone to promote maturation of the protein. Cell
surface labeling was performed after the indicated times at 37 C in 0.2
mg/mL cycloheximide. (C) Amounts of mature labeled CFTR at each
time point (B) quantitated and expressed relative to time zero.4395 dx.doi.org/10.1021/bi2004813 |Biochemistry 2011, 50, 4393–4395
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maturation and stability of CFTR processing mutants. Benzbro-
marone rescue of CFTR resembles drug rescue of P-gp proces-
sing mutants. Drug substrates bind to the TMDs of P-gp
processing mutants to increase the level of maturation, stability,
and activity at the cell surface.
16,27 Benzbromarone stabilization
of ΔF508 CFTR diﬀers from that of compounds that act
indirectly such as dynasore that stabilize CFTR by inhibiting
endocytotic internalization.
28,29
Benzbromarone rescue suggests that the TMDs of CFTR are
potential target sites for corrector molecules. Corrector mole-
cules have been identiﬁed using structure-based virtual screening
30
by docking at the interfaces between the cytoplasmic domains
butnotattheinterfacebetweentheTMDs.Apotentialdrawback
of targeting the TMDs is that compounds like benzbromarone
block the channel.
Couldacorrector moleculebindtoaregion oftheTMDsthat
does not block the pore? A recent study using a suppressor
mutation of P-gp suggests that it may be possible to identify
compounds that bind to intradomain sites outside of the pore to
promote maturation.
31 It has also been proposed that CFTR
contains a large intracellular vestibule.
32 The intracellular vesti-
bule may be large enough to accommodate a corrector molecule
without blocking the pore. Because benzbromarone is already
used to treat hyperuricemia and gout (see the Supporting
Information),itmaybepossibletoidentifyanaloguesthatrescue
ΔF508 CFTR without blocking the channel.
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